Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a...

|About: Ocera Therapeutics, Inc. (OCRX)|By:, SA News Editor

Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a subsidiary of Tranzyme Pharmaceuticals (TZYM) in an all-stock deal. The companies say the merged entity (which will assume the "Ocera" name and will be 72.6% owned by Ocera shareholders) will be a NASDAQ-listed company. Tranzyme will issue $20M in common stock and effect a reverse stock split concurrently with the closing of the deal. (See: TZYM to evaluate alternatives)